CSIR is developing vaccine candidates using different technology platforms
Our labs are working on novel proteins for vaccine development: CSIR
Aurobindo is already developing a vaccine for COVID19 through Auro Vaccines
Hyderabad: The Council of Scientific and Industrial Research (CSIR) and Aurobindo Pharma Limited on Tuesday (September 15) announced a collaboration to develop vaccines for COVID-19. As per the release issued by the Centre for Cellular & Molecular Biology (CCMB), under the signed agreement between CSIR- CCMB and Aurobindo Pharma, Aurobindo will partner with CSIR for the development of several novel COVID-19 vaccines.
“Three CSIR labs namely CCMB Hyderabad, Institute of Medical Technology (IMTECH), Chandigarh and Indian Institute of Chemical Biology (IICB), Kolkata are developing vaccine candidates using different technology platforms. Aurobindo will undertake clinical development and commercialization of the vaccines,” it said.
Commenting on this partnership, Dr Shekhar C Mande, Director General, CSIR, said that
Joining of hands of premier CSIR labs with industry for the development of vaccines will amplify India’s efforts in indigenous vaccine development and also help in preparedness for future pandemics.
Dr. Rakesh Mishra, Director, CSIR-CCMB, while talking about the development strategies for the vaccines said,
Our labs are working on novel proteins for vaccine development that has the potential to address the need for a second-generation vaccine. We are happy to partner with Aurobindo who have proven manufacturing and commercialization capabilities.
Aurobindo Pharma Limited also expresses pride over the collaboration with CSIR for developing vaccines to combat the COVID-19 pandemic and said that is already setting up a large-scale facility in Hyderabad for manufacturing the vaccine.
We are proud to join hands with CSIR for developing vaccines to combat the COVID-19 pandemic. This collaboration further strengthens our COVID-19 vaccine development efforts. We are already setting up a large-scale facility in Hyderabad for manufacturing COVID-19 vaccine and other viral vaccines, said N. Govindarajan, Managing Director, Aurobindo Pharma Limited.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.
Coronavirus has spread to 188 countries. The total confirmed cases worldwide are 3,22,27,134 and 9,82,949 have died; 90,11,771 are active cases and 2,22,32,414 have recovered as on September 25, 2020 at 3:43 am.
In India, there are 58,18,570 confirmed cases including 92,290 deaths. The number of active cases is 9,70,116 and 47,56,164 have recovered as on September 25, 2020 at 2:30 am.
According to Medical Director of Rajiv Gandhi Super Speciality Hospital, both Dengue and COVID-19 have no specific treatment, which makes it even difficult for treating doctors of patients with both diseases